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he term “parasite” derives from a classical Greek word 
that was used to refer to “a guest who comes to dinner 
and doesn’t leave” or “a class of priests who had meals 
at public expense” (Clitodemus, in Athenaeus Grammaticus, ca. 
378 B.C.). In modern usage, it refers to eukaryotic organisms 
that range from single-cell protozoa to complex multicellular 
worms. The diseases caused by these organisms represent 
some of the world’s greatest health problems. 
Malaria, for example, currently affects about 500 million 
people and causes about 3,000 deaths a day—mostly in sub-
Saharan Africa [1]. Schistosomiasis, caused by Schistosoma spp. 
(blood ﬂ  ukes), affects over 250 million people in the tropical 
world [2], and a recent meta-analysis showed that the disease 
is signiﬁ  cantly associated with anemia, chronic pain, diarrhea, 
exercise intolerance, and undernutrition [3]. Almost a 
billion people are infected with the nematode parasites: 
Ascaris (roundworm), Ancylostoma (hookworm), and Trichuris 
(whipworm) [2]. Why then have so few effective drugs been 
produced against these diseases? 
The answer lies primarily in the fact that these are diseases 
affecting people who are poor and living in poor regions 
of the world. They represent little or no viable market for 
the pharmaceutical industry, especially given the market 
requirements of the recently merged pharmaceutical giants. 
Given this reality, how can imaginative and effective strategies 
be developed to meet this challenge?
New Strategies for Antiparasitic Drug Design
At last year’s meeting of the American Society of Tropical 
Medicine and Hygiene, the organization that hosts one of the 
largest international gatherings of basic scientists and tropical 
medicine specialists, several symposia highlighted efforts in 
antiparasitic drug design. What was ﬁ  ve years ago a fairly dark 
vision of the future, now appears brighter. 
Several nonproﬁ  t organizations are now operating that are 
dedicated to this unmet medical need, some collaborative 
interest exists in industry, and philanthropies have backed 
new initiatives. There are also a number of new academic 
consortia with novel strategies to address issues of target 
discovery and preclinical development. 
Strategy one: Developing a drug that has both a 
commercial market in the west and an application against 
a neglected parasitic disease. This strategy is exempliﬁ  ed 
by the international consortium of researchers organized 
by Dr. Richard Tidwell of the University of North Carolina. 
With funding from the Bill and Melinda Gates Foundation, 
more than a dozen faculty and scientists from six research 
institutions (see Box 1) are working in collaboration 
with Immtech International to manage the “cross-over” 
development of antifungals produced by Immtech as 
potential drugs for African trypanosomiasis, also known as 
African sleeping sickness. This approach takes advantage of 
drug development of a class of compounds targeting a viable 
commercial market for Immtech (fungal diseases of the 
developed world). At the same time, academic- and nonproﬁ  t-
institute scientists are targeting these compounds in parallel 
toward an “unproﬁ  table” major health problem—African 
sleeping sickness. Speciﬁ  cally, an analog of the antifungal 
pentamidine has been optimized as a trypanocidal agent and 
is in clinical trials in Africa.
Strategy two: An academic consortium gets federal 
support for pharmacokinetic and toxicology studies. 
This second strategy is exempliﬁ  ed by work under the 
leadership of Dr. Donald Krogstad and colleagues at 
Tulane University. Here, without an industrial partner, 
Krogstad and colleagues are using in-house chemistry and 
computational assistance to modify chloroquine analogs 
in an effort to overcome the problem of chloroquine 
resistance in malaria treatment. Their main partner in this 
effort is the National Institute of Allergy and Infectious 
Diseases, which has provided support for pharmacokinetic 
and toxicology studies by virtue of pre-existing contracts 
with SRI International (an independent nonproﬁ  t research-
and-development organization) in Menlo Park, California, 
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Box 1. International Consortium Working with 
Immtech International to Develop Drugs for 
African Sleeping Sickness
• University of North Carolina–Chapel Hill 
• Georgia State University 
• London School of Hygiene and Tropical Medicine
• Ohio State University
• Swiss Tropical Institute
• Kenya Trypanosomiasis Research Institute
The Neglected Diseases section focuses attention either on a speciﬁ  c disease or 
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United States. At least one compound from this series is 
entering clinical trials.
Strategy three: An academic center uses a philanthropic 
gift to woo expertise from industry and build infrastructure 
for preclinical drug development. This third strategy is 
represented by the center that I direct, the Sandler Center 
for Basic Research in Parasitic Diseases at the University 
of California, San Francisco (UCSF). Here, philanthropic 
support was used to build infrastructure for a consortium 
of laboratories that mimics what might be found in a small- 
to medium-sized pharmaceutical company organized to 
carry out preclinical drug discovery and development. 
These core laboratories include computational support 
for drug discovery and chemical library selection, X-ray 
crystallography, drug metabolism and toxicology facilities, 
animal models of parasitic diseases, high-throughput 
screening, and synthetic chemistry. 
Initial work at this center focused on a drug lead for 
Chagas disease and was supported by a Tropical Disease 
Research Unit Program project grant from the National 
Institute of Allergy and Infectious Diseases. This compound, 
now a drug candidate, was originally synthesized by Dr. Jim 
Palmer of Khepri Pharmaceuticals (now Celera) as part of an 
industry search for anti-inﬂ  ammatory and anticancer drugs 
focusing on cysteine proteases. Validation of this compound 
as an antiparasitic was carried out by the UCSF team through 
rodent models of disease and, next, supported, as in the case 
of the Tulane consortium, by Dr. Chuck Litterst, Director 
of the National Institute of Allergy and Infectious Diseases 
Drug Development and Surveillance Group. The UCSF 
group initially handed over further development of a drug 
candidate to the Institute for OneWorld Health (iOWH), 
one of the nonproﬁ  t organizations that has sprung up to 
meet “downstream” drug development needs for neglected 
diseases (see Sidebar). iOWH facilitated tests of drug safety, 
minimum effective dose, and a formulation for large-scale 
Good Manufacturing Practice manufacture. The Drugs for 
Neglected Diseases Initiative (www.dndi.org) has now become 
the main partner for further development [4]. The Sandler 
Center consortium itself is now focusing on completing 
preclinical development of similar drug candidates 
targeting homologous enzymes in several other major global 
pathogens.
There is another way in which this third strategy represents 
a radical departure from the usual research paradigm of 
academic centers. A High-Throughput Screening Center has 
been established by the Sandler Center consortium, building 
upon the expertise of Drs. Kip Guy (now director of the 
center) and Janice Williams (now manager of the center), 
who brought an industrial perspective to the university. A 
recently completed screen used an assay that allowed robotic 
screening of a library of thousands of FDA-approved drugs 
and natural products for activity against Trypanosoma brucei, 
the parasite that causes African sleeping sickness. The “hit 
list” from this screen is being made available on a Web 
site (http:⁄⁄itsa.ucsf.edu/~schisto/fruit.html) for those 
organizations (such as the Drugs for Neglected Diseases 
Initiative [4], iOWH, and the World Health Organization) 
whose missions include licensing, manufacture, and 
distribution. Similar screens are being set up for leishmaniasis, 
Chagas disease, schistosomiasis, and malaria. 
A New Drug Pipeline
The success of these three unusual strategies, all originating 
within academic centers, provides a new drug pipeline for 
parasitic diseases with no market value for the pharmaceutical 
industry (Figure 1). The future is likely to see a number of 
academic or academic–industrial collaborations supporting 
preclinical development in consortia like those described 
above. 
This prediction was already borne out at the April 2005 
meeting, “Drug Development for Diseases of Protozoa,” 
sponsored by the Keystone Symposia. In the short time 
since the American Society of Tropical Medicine and 
Hygiene meeting, it has become clear that more academic 
laboratories are encouraged to pursue drug discovery 
and development avenues beyond research traditionally 
thought of as academic. New consortia modeled after 
the three described above are now functional or in 
late planning stages at the University of Washington, 
Johns Hopkins University, Harvard University, and the 
University of Dundee. In addition, signiﬁ  cant help from 
some large pharmaceutical companies, notably the Trés 
Institute for OneWorld Health 
iOWH (www.oneworldhealth.org) is a nonproﬁ  t 
pharmaceutical company founded in 2000 in San Francisco 
whose mission is to develop safe, effective, and affordable new 
medicines for people with infectious diseases in the developing 
world. The institute carries basic research forward through drug 
development—it identiﬁ  es drug leads, secures resources, and 
completes their development. For example, the organization 
recently received a grant of nearly US$10 million from the 
Bill and Melinda Gates Foundation to continue advancing its 
promising drug for visceral leishmaniasis, paromomycin, through 
the approval and post-approval process. 
DOI: 10.1371/journal.pmed.0020210.g001
Figure 1. The Pipeline of Drug Development
The success of the three strategies discussed in this article, all 
originating within academic centers, provides a new drug pipeline 
for parasitic diseases with no market value for the pharmaceutical 
industry.
DNDi, Drugs for Neglected Diseases Initiative; IMMTECH, Immtech 
International; MMV, Medicines for Malaria Venture; NIAID, National 
Institute of Allergy and Infectious Diseases; UNC, University of North 
Carolina–Chapel Hill. 
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Cantos laboratory of GlaxoSmithKline, has fueled focused 
academic- and nonproﬁ  t-organization drug development 
efforts. Three nonproﬁ  t organizations (the Drugs for 
Neglected Diseases Initiative, iOWH, and the Medicines for 
Malaria Venture) are actively working to support various 
stages of the drug-development pipeline. Their efforts 
are particularly key to the “downstream” elements of drug 
manufacture and clinical trials.
Finally, philanthropic organizations such as the Bill and 
Melinda Gates Foundation, the Sandler Family Supporting 
Foundation, and the Ellison Foundation have contributed 
to these endeavors. Their continued support, and the 
recruitment of other interested parties, will be crucial to 
maintaining the momentum engendered by the three 
projects outlined here.  
Editorial Note: PloS has received ﬁ  nancial support in the form of a 
grant from the Sandler Family Supporting Foundation.
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